Regulatory Requirements and Guidelines

23 – 27 January 2017
Faculty of Pharmacy, Universidade de Lisboa, Portugal
About SafeSciMET

SafeSciMET is a unique pan-European network of academia and pharmaceutical industry, which have joined forces to establish a comprehensive modular education and training in Safety Sciences for medicines. The programme covers all aspects of safety in drug development, in order to fulfil the needs of drug safety scientists in the pharmaceutical industry, regulatory authorities and academia. The aim of the programme is to bridge crucial gaps in the education and training of scientists evaluating the safety of drug candidates and new medicines and to ensure that European drug safety scientists are at the forefront of their field.

The course Regulatory Requirements and Guidelines and the other single courses of the SafeSciMET programme provide new opportunities for Continuous Professional Development (CPD) and are part of European Master for Advanced Safety Sciences for Medicines degree at the University of Konstanz. The individual courses are clustered within five separate domains. Each domain deals with one or more specialised topics and contains from two to six single courses. Please visit www.safescimet.eu for details of the full course programme and confirmation of course dates.

Course objectives

Drug development and production underlies laws and regulations to secure protection of human, test animals and the environment. Guidelines provide advice to applicants on specific scientific issues reflecting a harmonized EU approach to fulfil the pharmaceutical legislation. This course will provide participants with a comprehensive overview of the required in vitro and in vivo nonclinical studies, strategies for the development and risk assessment of new pharmaceuticals. While the focus of this course is mainly on the EU perspective, the ICH procedures and guidelines reflecting the international harmonization of requirements (in the EU, US and Japanese) are also covered. Special emphasis is put on the translational science methodologies for the transfer into humans of nonclinical data generated from integrated in vitro and animal models. The study needs for specific patient populations (pregnant women, paediatric, geriatric) are also part of this course's curriculum. At course completion students will have knowledge of the type and rationale of the tests required and will be able to determine which data need to be generated in each situation and for which stage of the development.

Key subjects covered by the course

- Drug development process and regulatory requirements
- EU & ICH guidelines and the Common Technical Document
- ICH guideline on nonclinical safety
- Extrapolation of animal data, human translation and risk assessment
- Species selection for nonclinical studies and 3Rs principles
- Reproductive toxicity testing, pregnancy labeling
- Testing genotoxic and carcinogenic potential
- First in Human studies and regulatory guidelines for safe dose estimation
- Nonclinical safety testing of biologics
- Environmental risk of pharmaceuticals
Target audience

SafeSciMET courses are open to all scientists and students from industry, academia and regulatory authorities, who need a broad comprehensive understanding of the drug development process with particular emphasis on safety. The applicant will normally possess an MSc degree in a Life Science discipline or equivalent. In addition, applicants are expected to have an at least one year working experience in a related discipline.

Why join the course?

The on-site training of the course in Lisbon during the first week consists of five days with lectures, practical exercises, group work and discussions. This setup offers an intense and broad training with leading experts in their field and ample opportunities for lecturer-student interactions. The balance of academic, industry and regulatory teachers provides knowledge directly available to drug safety assessment, including dataset discussions from real case studies.

Learning outcomes

On successful completion of the course, participants should have an integrated view on the regulatory requirements and guidelines relevant for the development and marketing of new pharmaceuticals. They will understand the type and rationale of the tests required and will identify which data is necessary in each stage of development. More specifically, participants will be able to:

- Understand the concept of “relevant species” and recognize the value of its use for human extrapolation of nonclinical study outcomes
- Plan the nonclinical safety programs for different types of pharmaceuticals and understand the translational aspects of medicines development
- Know and understand the European and international nonclinical regulatory guidelines and the situations where they will apply or deviate
- Adapt the standard protocols into specific situations, e.g. pathologies, patient populations
- Use and integrate the information from multiple sources / studies as a weight of evidence approach for human risk assessment
Course programme

The first week of the course in Uppsala consists of five days lectures, practical exercises, group work and discussions, provided by specialists from academia, pharmaceutical industry and regulatory authorities with diverse backgrounds on drug safety aspects.

On-site training

Day 1: Overview about the regulatory systems in the EU and harmonization issues
Day 2: ADME PK/PD, extrapolation from animal data to human
Day 3: Risk assessments on immunotoxicity and carcinogenicity
Day 4: Reproductive toxicity testing, First in Human guidelines
Day 5: Exploratory clinical trials; Patient populations

Individual home assignments

After the week of on-site training, students will receive an individual 38 hours home assignment consisting of written questions and a case study. These individual assignments are to be completed through a frequent exchange with the SafeSciMET teachers using distance learning approach. Written individual assignments are to be completed and submitted via Blackboard within 6 weeks after the on-site training and will then be approved by the course leader.

Course Credits

In order to receive the full 3 ECTS credits for a successfully completed course, participants need to pass the written exam of the on-site training week as well as to have successfully completed the home assignment.

Participants attending the on-site training week only, without completing the exam and/or the home assignment, will be given a certificate of attendance confirming completion of a Continuing Professional Development (CPD) course.

Feedback from the previous courses:

“Excellent way to work with so many case studies.”

“It was nice to be able to discuss with the teachers between the lectures.”
Syllabus

The purpose of the examination is to test that the examinee has acquired a broad knowledge and comprehension of the course subjects during the lectures. The percentage of items on the test devoted to a particular topic will roughly correspond to the emphasis given on the topic during the course.

Experimental Design: 25%
Pre-clinical/Manufacturing: 50%
Clinical: 5%
Translational: 20%

Assessors: Course leaders
Exam aids: All written exam aids are allowed, especially the provided material: lecture hand outs, list of abbreviations and case studies.

Assessment

The assessment is based on a 2-hour written examination on the last day of the first course week and on the evaluation of the home assignment.

Type: The purpose of the examination is to test that the examinee has acquired a broad knowledge and comprehension of the course subjects during the lectures.

Experimental Design: 25%
Pre-clinical/Manufacturing: 50%
Clinical: 5%
Translational: 20%

Contact person

Beatriz Silva Lima
Faculdade de Farmacia, Universidade de Lisboa
Avenida das Forças Armadas 1600 Lisboa, Portugal
beatrizlima@netcabo.pt

Course leaders

Professor Beatriz Silva Lima
Faculty of Pharmacy, Universidade de Lisboa, Avenida Professor Gama Pinto, 1649-003 Lisboa, Portugal

Director Per Spindler
Biopeople, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark

Dr. Kirstin Meyer
Bayer Pharma AG, Berlin, Germany
Practical information

Course credits 3 ECTS credits
Level Master’s level (second cycle higher education)
Course dates 23 – 27 January 2017
Location Faculty of Pharmacy, Universidade de Lisboa, Portugal
Teaching methods Lectures, case reports, demonstrations and home assignments.
Student workload Preparation: 12 hours
Course: 38 hours
Assignment: 38 hours
Examination: 2 hours
Total: 90 hours
Course fee 500 Euro – 2.500 Euro (dependant on category of student)
Please visit www.safescimet.eu How to apply for more information.
Application deadline 20 December 2016
Course capacity 20 participants
Language The official language of the course is English.
No simultaneous translations will be provided.
Course notes Complete course notes, except for the textbook, will be available for all the participants.
Course accreditation SafeSciMET courses meet the criteria for Continuous Professional Development (CPD) diplomas, and are part of the Master programme ‘Advanced Safety Sciences for Medicines’.
When registering for a “Stand Alone” courses of our programme, this course provides CPD credits for your individual CPD portfolio. Each course is credited with 38 contact hours.
The course setup is already consistent with the requirements of the Bologna process. The full Master program is implemented as a post-graduate MSc degree from the University of Konstanz/Germany.

Please note: More and the most up-to-date information can always be obtained from our website: www.safescimet.eu
Please check this site before registration.
Registration

Please visit www.safescimet.eu or https://afww.uni-konstanz.de/en/service/online-anmeldung/online-registration-safescimet-courses-regulatory-requirements to register. On the homepage, please go to How to Apply and choose to sign up for:

- single or multiple courses for Continuing Professional Development (CPD)
- MSc of Advanced Safety Sciences Courses (ECTS credits)

After you have applied as indicated above, your qualifications will be reviewed by the Student Office at Uppsala University and the SafeSciMET Admission Board. Within one week after the application deadline you will be informed upon your acceptance to the course.

The closing date to register for this course is 20 December 2016.

Please note that the number of participants is limited to 20. It is highly advisable to send in your registration form as soon as possible. Registration will be made on a first come first served basis.

Transport

The course takes place at the Lisbon University, 10 minutes by taxi from Airport and 5 minutes walking distance from Lisbon Sana Hotel.

Accommodation

We recommend reserving a room for your stay in Lisbon at the Lisboa Sana Metropolitan Hotel Rua Soeiro Pereira Gomes, Parcela 2, Entrecampos, 1600-198 Lisbon www.booking.com/SANA Metropolitan Hotel .

Otherwise, hotels can be arranged individually via Lisbon Tourist Information www.visitlisboa.com .

Cancellation

Cancellation of a pre-registered student is possible, upon written notice by 27 December 2016. Before that date the Course fee will be refunded except for an administrative fee of 75 Euro. After that date, no refunds can be made for cancellations.

Please use Karin.Rieder@uni-konstanz.de for cancellation.
Regulatory Requirements and Guidelines

Key questions addressed by the course

• Drug development process and regulatory requirements
• EU & ICH guidelines and the Common Technical Document
• ICH guideline on nonclinical safety
• Extrapolation of animal data, human translation and risk assessment
• Species selection for nonclinical studies and 3Rs principles
• Reproductive toxicity testing, pregnancy labeling
• Testing genotoxic and carcinogenic potential
• First in Human studies and regulatory guidelines for safe dose estimation
• Nonclinical safety testing of biologics
• Environmental risk of pharmaceuticals